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Background: The relative efficacy of a collar containing 10% imidacloprid and 4.5% flumethrin (Seresto®, Bayer
HealthCare Animal Health) and a spot on formulation containing 10% imidacloprid and 2.5% moxidectin (Advocate®,
Bayer HealthCare Animal Health) was evaluated as a control measure to prevent canine thelaziosis in dogs in an
endemic area of France.
Findings: Ninety-six privately-owned dogs were enrolled in the multicentre, controlled study. Before summer (the
period of transmission by fruit flies), dogs were allocated to one of three groups: Group A (n = 36)- treated once with
a collar containing 10% imidacloprid and 4.5% flumethrin; Group B (n = 33)- treated every month for 8 months with a
spot-on containing imidacloprid 10% and moxidectin 2.5%; and Group C (n = 27)- untreated control animals. Dogs
were regularly subjected to ocular examination in order to assess Thelazia callipaeda infection. During the trial,
T. callipaeda nematodes were detected in 12 (33%) collared dogs (group A) whereas no eyeworm could be found in
dogs who received a monthly spot on application of moxidectin (group B). In the control group, 8 (30%) dogs
became infected.
Conclusions: The monthly application of a spot on formulation containing 10% imidacloprid and 2.5% moxidectin
was shown to be highly effective in preventing T. callipaeda infection in a population of dogs living in an endemic
area in France. On the contrary, the slow-release collar tested in this study did not display any protection against
canine thelaziosis.
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Background
Thelazia callipaeda (Spirurida, Thelaziidae) is a nema-
tode that lives in the conjunctival sac of domestic and
wild carnivores, rabbits and humans causing mild to se-
vere clinical signs (epiphora, conjunctivitis, keratitis and
even corneal ulcers) [1]. In Europe, Thelazia callipaeda is
transmitted by Phortica variegata (Diptera, Drosophilidae),* Correspondence: jguillot@vet-alfort.fr
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unless otherwise stated.a small secretophagous fly. This insect feeds on fruits, veg-
etables and also on lacrymal secretions of domestic ani-
mals and wildlife [2]. In the past two decades T. callipaeda
infection was proved to be widespread among dogs and
cats from northern (Aosta valley) to southern (Basilicata
region) Italy [3,4]. Following the first descriptions in Italy,
T. callipaeda has been increasingly reported in western
France (Dordogne area) [5,6], Switzerland [7], Spain [8],
and Portugal [9]. Recently, the first autochthonous cases of
thelaziosis have been described in red foxes, dogs and a
cat living in Bosnia and Herzegovina and Croatia [10]. TheThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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endemic countries of Europe may be attributed to the dis-
persal of the infection with wild carnivores (especially red
foxes), which are suitable hosts for this parasite and may
easily move in neighbouring regions [11]. The growing
number of cases of canine thelaziosis in Europe is also a
consequence of the increased mobility of dogs and the ab-
sence of reliable preventive measures in pet carnivores. In
a previous investigation, monthly administration of milbe-
mycine oxime was shown to significantly reduce T. calli-
paeda infection rate in dogs in the field [12]. Milbemycine
oxime is the only molecule, which has been registered in
Europe for the treatment of canine thelaziosis. The mol-
ecule is used orally at 0.5 mg/kg and two administrations
at one week interval are recommended. Recently, a poly-
mer matrix collar containing a combination of 10% imi-
dacloprid and 4.5% flumethrin (Seresto®, Bayer HealthCare
Animal Health) has been licensed for use in dogs and cats.
This collar conferred long-term protection against fleas
and ticks [13]. It was successful in preventing the trans-
mission of tick or flea-borne pathogens [14,15] and a study
recently demonstrated its efficacy in the prevention of
infection by Leishmania infantum in dogs in a hyper-
endemic area in Italy [16].
The aim of this study was to determine whether appli-
cation of the slow-release insecticide collar containing
10% imidacloprid and 4.5% flumethrin could reduce T.
callipaeda transmission in dogs living in Dordogne,
France. The prophylactic activity of a spot-on formula-
tion containing moxidectin was also evaluated over the
9 month-study period (from May 2012 to January 2013).
Methods
Study site and selection of the dogs
Ninety-six dogs (46 males and 50 females, aged 11 months
to 15.6 years and weighting 5.4 to 54.8 kg) were enrolled
in the present trial. They were privately owned dogs who
lived in Dordogne, France. Before inclusion, informed
owner consent was obtained. Two veterinary clinics par-
ticipated to the selection and follow up of the animals.
These clinics are located in Vergt and Notre Dame de
Sanilhac, two small cities within a zone known to be en-
demic for T. callipaeda [6].
Dogs fulfilling the following inclusion criteria were
enrolled in the study: dogs in normal general health, ≥
7 weeks of age, ≥ 1 kg, not treated with ectoparasiticidal
products in the preceding months, and with a history of
previous infection by T. callipaeda (diagnosed in 2011
by direct examination of nematodes by NS or OP).
Study design
In May 2012, included dogs were assigned to one of the
three groups, A, B and C, using a random treatment allo-
cation plan. One month before the day of inclusion (D0) aspot on formulation containing 10% imidacloprid and
2.5% moxidectin (Advocate®, Bayer HealthCare Animal
Health) was administered to all the dogs in order to be
sure that the animals were not infected by T. callipaeda at
the beginning of the trial. Dogs were allocated to one of
three groups (A, B and C). At D0, dogs were checked
again for eyeworms and imidacloprid 10% + flumethrin
4.5% collars (Seresto®, Bayer HealthCare Animal Health)
were fitted to dogs (n = 36) from group A on the basis of
their body weight (i.e., small collar: < 8 kg/large collar: >
8 kg). Dogs (n = 33) from group B received a monthly
dose of imidacloprid 10% and moxidectin 2.5% by spot-on
dermal application (Advocate®, Bayer HealthCare Animal
Health), in accordance with the dogs’ body weight and
following the label instructions. Dogs from group B were
treated 8 times (from May to December 2012). Dogs
(n = 27) from group C were left untreated and served as
controls. Dogs from group A and C were examined on days
0, 120 and 240 after inclusion. Dogs from group B were ex-
amined every month (just before the application of the spot
on) until day 240. During the trial, owners were asked to
present their dogs to the consultation as soon as ocular
clinical signs occurred. For each dog and each follow-up,
the presence of T. callipaeda was carefully investigated by
ocular examination. Dogs were restrained with a muzzle
and the conjunctival fornix inspected for the presence of
nematodes using a sterile cotton swab. An approximate
count of nematodes number was made for each eye. Nema-
todes were stored in 70% ethanol and sent to the Parasi-
tology department of Veterinary College of Alfort, France
for morphological identification according to Skrjabin et al.
[17] and Otranto et al. [18]. Infected dogs were treated by
the application of the moxidectin spot on formulation.
The use of other ectoparasiticides on dogs was not
allowed throughout the study period. However, individual
treatments (with a product without any repellent activity)
were authorized when heavy tick or flea infestations oc-
curred. Due to the nature of the investigational veterinary
product (collar), blinding was not applicable.
Statistical analysis
The efficacy evaluation was based on the comparison of
the incidence of T. callipaeda-infected dogs in the two
treatment groups (A and B) versus the control group
(C). Incidence was calculated as follows: number of dogs
newly infected with T. callipaeda/(number of negative
dogs initially enrolled - number of lost or dead dogs) × 100.
Statistical associations were quantified using preva-
lence rates of T. callipaeda in each of the 3 groups, and
were tested using the Chi-2, or Fisher exact (when ne-
cessary), statistical test. Factors associated with higher
prevalence rates of T. callipaeda were also investigated
using the Chi-2 or Fisher exact statistical test. Statistical
analyses were performed using Epi-Info (Centers for
Figure 1 Conjunctivitis and Thelazia callipaeda specimens in an
untreated control dog (Noémie Siméon).
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Organization, Geneva, Switzerland). Significance level
was reached if p-values were < 0.05.
Results
During the trial, T. callipaeda nematodes were detected
in 12 (33%) of the 36 collared dogs (group A) whereas
no eyeworm could be found in the 33 dogs who received
a monthly spot on application of moxidectin (group B).
In the control group C, 8 (30%) of the 27 dogs had eye-
worms indicating that dogs living in the study area had
been naturally exposed to T. callipaeda during the sum-
mer of 2012. There was no significant difference be-
tween the incidence of T. callipaeda infection in groups
A and C. As a consequence, the slow-release insecticideTable 1 Baseline characteristics of groups A (dogs treated wit
C (untreated dogs)
Parameters Group A (n = 36) Seresto®
Pure breed, n (%) 26 (72.2%)
Hair length, n (%)
Short hair 16 (44.5%)
Medium hair 12 (33.3%)
Long hair 8 (22.2%)
Median age [IQR] (years) 5.7 [3.1-8.5]
Male, n (%) 19 (52.8%)
Contact with other carnivores, n (%) 30 (83.3%)
Living in rural area (versus city), n (%) 35 (97.2%)




Median body weight [IQR] (kg) 24.8 [17.7-29.2]
IQR, Interquartile range.collar tested in this study did not provide any protection
against canine thelaziosis. No signs suggestive of adverse
reactions were recorded in treated dogs (either collared
or treated with the spot on). Heavy tick or flea infesta-
tions never occurred during the trial. As a consequence,
no additional insecticide or acaricide treatment was
necessary.
One month before inclusion (in April 2012), out of the
overall 96 dogs, 30 (31%) were already infected by T. cal-
lipaeda. During the trial, 20 additional cases were de-
tected. Seven dogs were infected twice (before inclusion
and during the trial). In 12 cases, no clinical signs were
detected. In other cases (n = 38), the following clinical signs
were most frequently observed: conjunctival hyperemia
(87%), lacrimation (50%), ocular mucopurulent discharge
(24%) and chemosis (11%) (Figure 1).
The statistical analysis revealed that the frequencies of
the variable parameters were not significantly different
among groups (Table 1).
Discussion
The present study demonstrated that the monthly appli-
cation of a spot on formulation containing imidacloprid
and moxidectin was highly effective in preventing T. cal-
lipaeda infection in a population of dogs living in an en-
demic area in France. On the contrary, the slow-release
collar tested in this study did not display any protection.
To our knowledge, only two trials were performed in
order to evaluate the prophylactic activity of antiparasitic
drugs against T. callipaeda. Rossi et al. evaluated the effi-
cacy of a single parenteral administration of moxidectin
in naturally exposed dogs in northern Italy [19]. In June
2005, 31 dogs were injected subcutaneously with ah Seresto®), B (dogs treated with Advocate®) and
Group B (n = 33) Advocate® Group C (n = 27) P value
26 (78.8%) 16 (59.3%) 0.25
11 (33.3%) 7 (25.9%) 0.59
14 (42.4%) 14 (51.9%)
8 (24.3%) 6 (22.2%)
5.8 [2.4-9.8] 4.5 [2.8-7.4] 0.97
13 (39.4%) 14 (51.9%) 0.48
25 (75.8%) 17 (63%) 0.18
32 (97%) 25 (92.6%) 0.61
7 (21.2%) 6 (22.2%) 0.98
26 (78.8%) 21 (77.8%)
0 (0%) 0 (0%)
26.0 [15.8-29.5] 24.5 [19.3-34.1] 0.80
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0.17 mg/kg) and 32 dogs served as untreated controls.
At the end of the trial in January 2006, none of the
moxidectin-treated dogs had eyeworms whereas 11
(34%) of the control dogs did. A similar investigation
was made to evaluate the prophylactic efficacy of mil-
bemycin oxime [12]. Thirty dogs were treated with oral
milbemycin oxime monthly from June to November
2007 with the recommended dose rate for the preven-
tion of heartworm disease and 30 dogs served as un-
treated controls. One dog in the treated group and 10
dogs in the control group became infected during the
trial [12]. As macrocyclic lactones (like moxidectin and
milbemycin oxime) have a limited effect on vectors (like
the fruit fly P. variegata), the prophylactic efficacy of these
drugs is accounted by their activity against T. callipaeda
larvae a short time after they are deposited in the lacrymal
secretions by a fruit fly. The therapeutic efficacy of the
spot on formulation containing 10% imidacloprid and
2.5% moxidectin was demonstrated in naturally infected
dogs in Italy [20]. Elimination of T. callipaeda was ob-
tained within 5 or 9 days after treatment.
The use of an insecticide that could limit the exposure
of dogs to contaminating fruit flies is another prophylactic
strategy. The use of collars impregnated with acaricidal/
repellent compounds has provided promising results, indi-
cating that long-lasting protection of dogs against major
canine vector-borne diseases can be achieved in most in-
stances [14]. In the present study, the final incidence of
thelaziosis in collared dogs and in control animals was not
significantly different suggesting that the polymer matrix
collar containing a combination of imidacloprid and flu-
methrin would not provide any protection against canine
thelaziosis in field conditions. The amount of active ingre-
dients released by the collar that reach the skin area where
the fruit fly uses to land on and the short contact time are
probably not sufficient to ensure a repellent activity
against fruit flies or to kill them before they are able to
feed and transmit T. callipaeda larvae.
Conclusion
As a conclusion, the prevention of canine thelaziosis is
possible with a systemic anthelmintic molecule like moxi-
dectin. For dogs living in endemic areas, the monthly ad-
ministration of systemic macrocyclic lactones throughout
the transmission season (summer) should be recom-
mended. For pets spending no more than one month in
endemic areas, a single treatment, usually soon after
returning home, should be sufficient to assure complete
protection.
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